We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies
Product News

Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies

Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies
Product News

Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Data was presented at the recent American Society of Clinical Oncology's 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer.

This Phase III trial validated plasma cytokine and angiogenic biomarkers using Aushon’s multiplex immunoassay platform.

The University of Texas MD Anderson Cancer Center also reported results from a Phase II study earlier last year, which demonstrated excellent correlation between Aushon’s platform and the ELISA across multiple biomarkers.

“Until now, the single-plex ELISA has been the 'gold standard' for protein biomarker analysis in late stage clinical trials due to its perceived reliability”, said Peter Honkanen, CEO of Aushon.

Honkanen continued, “Data from these Phase II and Phase III studies demonstrate that Aushon’s multiplex technology can perform as well as the ELISA, while providing all the other benefits of a next-generation, multiplex platform including convenience, reduced sample consumption, higher throughput and lower cost performance. This clearly demonstrates that Aushon's technology has met the stringent expectations in a late stage clinical trial setting where the performance bar is very high.”

Advertisement